Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma.

Subjects

Subjects :

Aged
Female
Humans
Male
Monitoring, Physiologic
Multiple Myeloma genetics
Multiple Myeloma pathology
Survival Analysis
Antineoplastic Combined Chemotherapy Protocols therapeutic use
High-Throughput Nucleotide Sequencing methods
Multiple Myeloma drug therapy
Neoplasm, Residual physiopathology

Details

Language :

English

ISSN :

1476-5551

Volume :

31

Issue :

6

Database :

MEDLINE

Journal :

Leukemia

Publication Type :

Academic Journal

Accession number :

28210002

Full Text :

https://doi.org/10.1038/leu.2017.58